Expert on Hemp/Cannabis policy, ex member of the Croatian Ministry of Health regulatory commission for medical cannabis, Ilesol Pharmaceuticals' CEO
Ilesol Pharmaceuticals is proud to announce that EIHA’s CBD isolate dossier, RP427, has finally been validated by the UK’s Food Standards Agency (FSA), after a long-awaited process. This validation marks an important milestone for our company and for all members of Novel Food Consortium. We are excited to move to the next stage of the process – the risk assessment stage.
Moving forward, we are eager to continue working with the FSA during the risk assessment stage. This stage will involve the FSA reviewing and assessing the toxicological data that we have submitted. We are confident that our studies will demonstrate the safety and quality of our CBD products, and we look forward to the next positive steps.
In addition to our progress with CBD isolate, EIHA has also been conducting toxicology studies on full-spectrum CBD products. We are pleased to announce that these studies have been completed, and we will soon be submitting them to the European Food Safety Authority (EFSA) for review.
Furthermore, we are excited to announce that we will be conducting a THC tolerability study on 400 individuals later this year. This study is currently the only one of its kind in the world and will provide important data on the No Observed Adverse Effect Level (NOAEL) for THC in food. We believe this study will play a significant role in setting standards for THC levels in food and will provide valuable information to the industry as a whole.
At Ilesol Pharmaceuticals, we are committed to providing high-quality, safe, and effective CBD products to our customers. We believe that CBD has the potential to provide many benefits and improve people’s quality of life. We are excited about the progress we have made so far and are committed to continuing to work towards bringing our CBD products to market.